AP2377A - Benzimidazole derivatives. - Google Patents

Benzimidazole derivatives.

Info

Publication number
AP2377A
AP2377A AP2009005089A AP2009005089A AP2377A AP 2377 A AP2377 A AP 2377A AP 2009005089 A AP2009005089 A AP 2009005089A AP 2009005089 A AP2009005089 A AP 2009005089A AP 2377 A AP2377 A AP 2377A
Authority
AP
ARIPO
Prior art keywords
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
AP2009005089A
Other languages
English (en)
Other versions
AP2009005089A0 (en
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2009005089A0 publication Critical patent/AP2009005089A0/en
Application granted granted Critical
Publication of AP2377A publication Critical patent/AP2377A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2009005089A 2007-06-29 2008-06-16 Benzimidazole derivatives. AP2377A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (en) 2007-06-29 2008-06-16 Benzimidazole derivatives

Publications (2)

Publication Number Publication Date
AP2009005089A0 AP2009005089A0 (en) 2009-12-31
AP2377A true AP2377A (en) 2012-03-07

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009005089A AP2377A (en) 2007-06-29 2008-06-16 Benzimidazole derivatives.

Country Status (46)

Country Link
US (2) US8148401B2 (da)
EP (1) EP2170860B9 (da)
JP (2) JP4567099B2 (da)
KR (1) KR101143246B1 (da)
CN (1) CN101687841B (da)
AP (1) AP2377A (da)
AR (1) AR067346A1 (da)
AU (1) AU2008272641B2 (da)
BR (1) BRPI0813412B8 (da)
CA (1) CA2690953C (da)
CL (1) CL2008001922A1 (da)
CO (1) CO6160232A2 (da)
CR (1) CR11150A (da)
CU (1) CU23847B1 (da)
CY (2) CY1118650T1 (da)
DK (1) DK2170860T5 (da)
DO (1) DOP2009000278A (da)
EA (1) EA016888B1 (da)
EC (1) ECSP099803A (da)
ES (1) ES2609258T3 (da)
FR (1) FR20C1038I2 (da)
GE (1) GEP20125702B (da)
GT (1) GT200900328A (da)
HK (1) HK1139658A1 (da)
HN (1) HN2008000974A (da)
HR (1) HRP20161562T2 (da)
HU (2) HUE030052T4 (da)
IL (1) IL202420A (da)
LT (2) LT2170860T (da)
MA (1) MA31466B1 (da)
ME (1) ME00962B (da)
MY (1) MY148636A (da)
NI (1) NI200900219A (da)
NL (1) NL301057I2 (da)
NO (1) NO2020027I1 (da)
NZ (1) NZ581889A (da)
PA (1) PA8785401A1 (da)
PE (2) PE20090772A1 (da)
PL (1) PL2170860T3 (da)
PT (1) PT2170860T (da)
RS (1) RS55395B9 (da)
SI (1) SI2170860T1 (da)
TN (1) TN2009000544A1 (da)
TW (1) TWI371451B (da)
UY (1) UY31164A1 (da)
WO (1) WO2009004427A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004427A2 (en) * 2007-06-29 2009-01-08 Pfizer Inc. Benzimidazole derivatives
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
NZ598749A (en) 2009-08-26 2013-01-25 Takeda Pharmaceutical Fused heterocyclic ring derivative and use thereof
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Nttドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012122370A2 (en) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
CN103814024B (zh) * 2011-09-26 2016-11-23 默克专利股份公司 作为溶血磷脂酸(lpa)受体拮抗剂的苄基哌啶化合物
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
CN107531667A (zh) * 2015-04-24 2018-01-02 辉瑞公司 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048154A1 (en) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233823D1 (de) * 2001-07-27 2009-11-05 Curis Inc N und relevante verwendungszwecke
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
EP1678145A2 (en) 2003-10-28 2006-07-12 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
WO2009004427A2 (en) * 2007-06-29 2009-01-08 Pfizer Inc. Benzimidazole derivatives
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
CN102203067B (zh) 2008-08-25 2014-01-15 Irm责任有限公司 Hedgehog通路调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048154A1 (en) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase

Also Published As

Publication number Publication date
HRP20161562T1 (hr) 2016-12-30
PE20121010A1 (es) 2012-08-06
CA2690953C (en) 2012-10-02
AR067346A1 (es) 2009-10-07
EA016888B1 (ru) 2012-08-30
BRPI0813412A2 (pt) 2014-12-30
PL2170860T3 (pl) 2017-05-31
HUS2000031I1 (hu) 2020-09-28
SI2170860T1 (sl) 2017-01-31
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
MA31466B1 (fr) 2010-06-01
TN2009000544A1 (fr) 2011-03-31
US8148401B2 (en) 2012-04-03
CY2020028I1 (el) 2020-11-25
CU20090225A7 (es) 2012-02-15
WO2009004427A3 (en) 2009-06-04
FR20C1038I2 (fr) 2021-08-13
NZ581889A (en) 2011-05-27
EP2170860A2 (en) 2010-04-07
JP2010531869A (ja) 2010-09-30
LT2170860T (lt) 2017-01-10
JP2010280693A (ja) 2010-12-16
CR11150A (es) 2010-02-08
US20090005416A1 (en) 2009-01-01
GT200900328A (es) 2011-08-29
NL301057I2 (nl) 2020-09-10
CY2020028I2 (el) 2020-11-25
CN101687841A (zh) 2010-03-31
TWI371451B (en) 2012-09-01
LTC2170860I2 (lt) 2022-03-10
AU2008272641B2 (en) 2013-08-29
TW200911792A (en) 2009-03-16
HUE030052T2 (hu) 2017-04-28
RS55395B9 (sr) 2020-01-31
UY31164A1 (es) 2009-01-30
CO6160232A2 (es) 2010-05-20
ECSP099803A (es) 2010-01-29
PA8785401A1 (es) 2009-01-23
EP2170860B1 (en) 2016-11-02
KR20100028120A (ko) 2010-03-11
CN101687841B (zh) 2013-07-10
AP2009005089A0 (en) 2009-12-31
DOP2009000278A (es) 2009-12-31
HN2008000974A (es) 2011-01-24
DK2170860T3 (da) 2017-01-09
AU2008272641A1 (en) 2009-01-08
JP4567099B2 (ja) 2010-10-20
NL301057I1 (nl) 2020-07-22
WO2009004427A2 (en) 2009-01-08
HK1139658A1 (en) 2010-09-24
BRPI0813412B1 (pt) 2020-01-21
KR101143246B1 (ko) 2012-05-18
DK2170860T5 (da) 2017-03-20
CU23847B1 (es) 2012-10-15
HUE030052T4 (en) 2017-06-28
US20120157495A1 (en) 2012-06-21
CL2008001922A1 (es) 2009-01-02
IL202420A0 (en) 2010-06-30
LTPA2020528I1 (lt) 2020-09-25
PT2170860T (pt) 2017-01-04
RS55395B1 (sr) 2017-04-28
GEP20125702B (en) 2012-12-10
EP2170860B9 (en) 2017-02-22
EA200971104A1 (ru) 2010-06-30
BRPI0813412B8 (pt) 2021-05-25
ME00962B (me) 2012-06-20
CA2690953A1 (en) 2009-01-08
NO2020027I1 (no) 2020-08-11
CY1118650T1 (el) 2017-07-12
MY148636A (en) 2013-05-15
HRP20161562T2 (hr) 2017-04-21
ES2609258T3 (es) 2017-04-19
IL202420A (en) 2014-05-28
FR20C1038I1 (da) 2020-10-02

Similar Documents

Publication Publication Date Title
HUS2000031I1 (hu) Benzimidazol-származékok
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
HK1149756A1 (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
EP2120569A4 (en) SPIROCHROMANONDERIVATE
IL202020A0 (en) Spiroindolinone derivatives
IL202830A0 (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
AP2010005345A0 (en) Indazole derivatives.
IL202667A0 (en) Isoxazole-imidazole derivatives
IL209733A0 (en) New benzimidazole derivatives
IL193475A0 (en) Benzimidazole derivatives
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2133347A4 (en) 1-BIARYLAZETIDINONDERIVATE
HK1141009A1 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
EP2172454A4 (en) benzimidazole derivative
IL211806A0 (en) New benzimidazole derivatives
HK1146276A1 (en) Thiadiazinone derivatives
EP2204368A4 (en) 4-SULFONYLPIPERIDINE DERIVATIVES
ZA200908626B (en) Benzimidazole Derivatives
ZA201000311B (en) Sulfonyl-quinoline derivatives
GB0702266D0 (en) 7-Azaindoe derivatives
AP2009005065A0 (en) Sulfonyl-quinoline derivatives